A CHARITY which represents people with MS has criticised a decision to deny approval of a new drug for treating the condition. The National Institute for Health and Care Excellence (NICE) - the regulator which approves new treatments and drugs for use by the NHS in England and Wales - has provisionally decided not to recommend ozanimod – a new, oral treatment for people with relapsing MS . The treatment would have been used to help those with relapsing multiple sclerosis. Oral treatments for this form of the condition are limited and the MS Society says ozanimod could have benefitted from a new, more convenient alternative .